ATOSSA THERAPEUTICS INC.
17.57
USD
(+0.92%)
03/14/2025 - 16:45
Open 15 min delayed data - NASDAQ Stocks
| Open: | 17.53 |
| Change: | +0.16 |
| Volume: | 34,256 |
| Low: | 17.30 |
| High: | 17.61 |
| High / Low range: | 0.31 |
| Type: | Stocks |
| Ticker: | ATOS |
| ISIN: |
ATOSSA THERAPEUTICS INC. news, videos and press releases - Page 4
For more news please use our advanced search feature.
ATOSSA THERAPEUTICS INC. - More news...
ATOSSA THERAPEUTICS INC. - More news...
- 05/09/2022 - 20:05 Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
- 04/27/2022 - 13:30 Atossa Therapeutics to Present at the Q2 Investor Summit Conference
- 04/20/2022 - 13:30 Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
- 03/23/2022 - 13:30 Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
- 03/08/2022 - 14:15 Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen
- 02/28/2022 - 21:15 Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update
- 01/27/2022 - 14:30 Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022
- 01/18/2022 - 14:30 Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201
- 12/22/2021 - 14:30 Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden
- 12/06/2021 - 14:15 Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration
- 11/24/2021 - 14:30 Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”
- 11/15/2021 - 14:30 Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
- 10/21/2021 - 13:30 Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
- 09/30/2021 - 13:30 Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia
- 09/07/2021 - 21:20 Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote
- 09/02/2021 - 13:30 Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden
- 08/13/2021 - 13:30 Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting
- 08/05/2021 - 13:30 Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021
- 07/30/2021 - 14:55 Thinking about buying stock in Erytech Pharma, NanoVibronix, Atossa Therapeutics, Allied Healthcare, or Camber Energy?
- 07/14/2021 - 13:31 Thinking about buying stock in Ashford Hospitality Trust, Clovis Oncology, Exela Technologies, Wipro, or Atossa Therapeutics?
- 07/07/2021 - 13:30 Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia
- 06/30/2021 - 15:15 Thinking about buying stock in Check Cap, ContextLogic, Marin Software, Atossa Therapeutics, or Altimmune?
- 06/28/2021 - 14:55 Thinking about buying stock in ContextLogic, Atossa Therapeutics, Marin Software, BEST, or BioNano Genomics?
- 06/23/2021 - 14:45 Thinking about buying stock in Acasti Pharma, Globalstar, ContextLogic, Atossa Therapeutics, or Ideanomics?
- 06/21/2021 - 13:31 Thinking about buying stock in MediciNova, Torchlight Energy, Atossa Therapeutics, Globus Maritime, or ContextLogic?
- 06/16/2021 - 13:00 Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes
- 06/11/2021 - 13:00 Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density
- 06/09/2021 - 15:00 Thinking about buying stock in BlackBerry, Atossa Therapeutics, UWM Holdings, Farmmi, or Root?
- 06/07/2021 - 13:00 Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021
- 05/17/2021 - 13:31 Thinking about buying stock in Apellis Pharmaceuticals, Purple Innovation, Atossa Therapeutics, Triterras, or Remark Holdings?
